Rare Disease Day is an international day of recognition to raise awareness for conditions affecting fewer than 1 in 2,000 people and the impact they
The Hematology, Oncology Point of Care through Survivorship Research Endowment Fund will support research by nurses and advanced practice practitioners aimed at addressing any stage
On Thursday, Aug. 8, 2024, Hyundai Hope On Wheels® awarded Children’s Minnesota and Dr. Michael Richards, lead investigator for pediatric oncology, with a $100,000 Impact
Dr. Stuart Winter, chief research officer, is one of 52 authors on a paper that was published in “Nature,” the world’s leading multidisciplinary science journal.
Treatment for B-cell and T-cell lineage acute lymphoblastic leukemia (B-ALL and T-ALL) has historically been similar. However, a distinct biology between these subtypes identified in
Children’s Minnesota is pleased to announce that Dr. Anne Bendel, pediatric neuro-oncologist in the health system’s cancer and blood disorders program, has been named as
A recent study by Dr. Gabrielle Hester, medical director of the department of value and clinical excellence and pediatric hospitalist at Children’s Minnesota, determined that
Dr. Kris Ann Schultz, pediatric oncologist at Children’s Minnesota, has been named a senior investigator in the EDISYN Collaboration! Dr. Schultz explains the what’s involved
The pharmacogenomics program at Children’s Minnesota is the only pediatric-focused program in the Upper Midwest and one of only a few pharmacogenomics programs in the
Reach us 24/7 for patient referrals, consults, admissions and neonatal transport.
© 2025 Children’s Minnesota
Children’s Minnesota is registered as a 501(c)(3) non-profit organization. Our tax identification number is 41-1754276.